back to search abstracts online

Sunday January 30,2000	Monday January 31, 2000	Tuesday February 1, 2000	Wednesday February 2, 2000
Abstract 209. The HIV-1-Specific CD8+ T Cell Response in Primary HIV-1 Infection Abstract 210. Decay Rates of Cell-Associated HIV-1 DNA Correlate with Residual Viral Replication in Patients Treated during Primary HIV-1 Infection Abstract 211. Early Therapy of Vertical HIV-1 Infection: Evidence for Cessation of Viral Replication and Absence of Virus-Specific Immunity Abstract 212. Primary Infection with HIV-1 with Reduced Drug Susceptibility Does Not Appear to Result from Point Source Transmission Abstract 213. Newly Derived HIV-1 Group N and SIVcpz (P.t.t.) Strains Cluster Together in the HIV-1/SIVcpz Lineage Abstract 214. Phylogenetic Analysis and Subtyping of HIV-1 Group O Abstract 215. Surveillance of HIV-1 Subtypes in the United States, 1998-Present Abstract 216. Frequency of New HIV Variants among HIV-Seropositive Individuals Worldwide Abstract 217. Block to HIV-1 Assembly in Murine Cells Abstract 218. Cell Cycle G2 Arrest Induced by HIV-1 Vpr through a Novel Cellular Pathway in Fission Yeast Abstract 219. HIV-1 Vpr Interferes with Cell Cycle Signaling Cascades by Interacting with the Ba Subunit of Protein Phosphatase 2A (PP2A) Abstract 220. Identification of the Nef-Associated Kinase as P21-Activated Kinase 2 Abstract 221. HIV-1 Nef Attenuates Fas- and TNFa-Induced Apoptosis by Inhibiting Apoptosis-Signal Regulating Kinase 1 (ASK1): Potential Role in Prolonging Survival of the HIV-1-Infected Cell Abstract 222. Unusual Polymorphisms in Human Immunodeficiency Virus Type 1 Associated with Nonprogressive Infection Abstract 223. Molecular Characterization of New Primate Lentiviruses from DeBrazza, Mona, and Blue Monkeys: Evidence for Host-Dependent Evolution within This Group of Viruses Abstract 224. HIV-1 Is Not Rapidly Cytopathic for Directly Infected Normal Human T Cells in vitro Abstract 225. Less Aggressive Disease and Longer Survival in AIDS-Related Lymphomas during HAART Abstract 226. Increased Expression of Stromal-Cell Derived Factor-1 in Peripheral Blood Mononuclear Cells Obtained from Children with AIDS-Related Lymphoma Abstract 227. A Chimeric Peptide for the Detection of Antibodies to Human Herpesvirus 8 Abstract 228. Maternal-Infant Transmission of Human Herpesvirus Type 8 (HHV-8) in Zambia Abstract 229. Pneumocystis carinii Mutations Are Associated with Duration of Sulfa Prophylaxis and with Sulfa Treatment Failure in AIDS Patients Abstract 230. Discontinuation of Toxoplasmic Encephalitis Prophylaxis Is Safe in HIV-1 and T. gondii Co-Infected Patients after Immunological Recovery with HAART. Preliminary Results of the GESIDA 04/98-B Study Abstract 231. Valganciclovir (VGCV) vs. IV Ganciclovir (GCV) as Induction Therapy for Newly Diagnosed Cytomegalovirus (CMV) Retinitis: A Randomized, Controlled Study Abstract 232. A Multicenter Randomized Trial Comparing Amphotericin B (AmB) and Liposomal Amphotericin B (AmBisome, LAmB) as Induction Therapy of Disseminated Histoplasmosis (DH) in AIDS Patients Abstract 233. Measuring the Replicative Fitness of Recombinant HIV-1 Vectors Expressing Protease and Reverse Transcriptase Derived from Patient Viruses Abstract 234. Reduced Susceptibility to NRTI Is Associated with NNRTI Hypersensitivity in Virus from HIV-1-Infected Patients Abstract 235. Salvage Therapy with Saquinavir SGC (SQV) in Combination with Ritonavir (RTV) or Nelfinavir (NFV) Plus Delavirdine (DLV), Adefovir Dipivoxil (ADV), or Both - ACTG 359 Abstract 236. Delayed Immunologic Deterioration among Patients Who Virologically Fail Protease Inhibitor-Based Therapy Abstract 237. Phenotypic Resistance Testing Significantly Improves Response to Therapy (Tx): A Randomized Trial (VIRA 3001) Abstract 238. Selection of Antiretroviral Resistance in the Latent Reservoir of Human Immunodeficiency Virus Type 1 during Successful Therapy Abstract 239. Relationship between Preexisting Latent Viral Reservoirs and the Reemergence of Plasma Viremia after Discontinuation of Highly Active Antiretroviral Therapy Abstract 240. Influence of Interleukin-2 (IL-2) on Productive and Latent HIV Infection and on Viral Rebound Abstract 241. Low Rates of All Opportunistic Infections among Patients with Advanced HIV Disease Responding to Antiretroviral Therapy - the CPCRA 048 Cohort Abstract 242. Prevention of Opportunistic Infections Other than Mycobacterium avium Complex (MAC) in a Randomized, Placebo-Controlled Trial of Azithromycin (AZ) Prophylaxis in Subjects with Increases in CD4 Cells on Antiretroviral Therapy (ART) - Preliminary Results Abstract 243. Discontinuing Primary and Secondary PCP Prophylaxis in Patients Who Have Increased CD4 Counts in Response to Antiretroviral Therapy: Preliminary Results - ACTG 888 Abstract 244. The Swiss StopCox Study: Is It Safe to Discontinue PCP Prophylaxis in Patients with Detectable Viremia, Low Nadir CD4 Count or T. gondii Seropositivity? Abstract 245. Indinavir and Other HIV Protease Inhibitors Decrease Pneumocystis carinii In Vitro Growth Abstract 246. Discontinuing or Withholding Primary Prophylaxis against M. aviumin Patients on Successful Antiretroviral Combination Therapy: The Swiss HIV Cohort Experience Abstract 247. Prophylaxis for Mycobacterium avium Complex Can Be Deferred among Patients with a Past CD4 Count <50 cells/mm3 Who Responded to Antiretroviral Therapy: Results of a Placebo-Controlled Trial (CPCRA 048) Abstract 248. Short-Course 2-Month Regimen for Latent M. tuberculosis Infection in HIV-Infected Patients in Broward County, FL Abstract 249. Immunogenicity of Revaccination with Pneumococcal Vaccine in HIV-Infected Patients on Combination Antiretroviral Therapy Abstract 250. Discontinuation of Antifungal Therapy for Cryptococcosis after Immunologic Response to Antiretroviral Therapy Abstract 251. Evidence for the Involvement of Matrix Metalloproteinase 9 in the Induction of HIV-1 in Mycobacterial Coinfections Abstract 252. Antiretrovirals Can Restore Anti-Mycobacterial T Cell Responses and Control Fatal Tuberculosis-Like Disease in SIV/Mycobacterium bovis BCG-Coinfected Monkeys Abstract 253. Risk Factors for Disseminated MAC (dMAC) in MAC II: Role of Preexisting Mycobacterial Antibody and Exposure to Colonized Water Abstract 254. Frequency of Isolation of M. avium complex (MAC) from Marrow in Patients Suspected of Disseminated MAC (DMAC) but with Negative Blood Cultures. Abstract 255. Impact of Combination Antiretroviral Therapy on the Risk of Tuberculosis among Persons with HIV Abstract 256. Does Tuberculosis (TB) Treatment Alter Immunological and Virological Response to HAART? Abstract 257. Localized Mycobacterial Immune Reconstitution Syndrome (LMIRS): Long-Term Outcome and Discontinuation of Mycobacterial Therapy (MRx) Abstract 258. CNS Manifestations of Paradoxical Reaction in HIV+ TB Patients on HAART Abstract 259. Treatment of Tuberculosis (TB) in HIV-Infected Patients: A Complicated Course of Therapy Abstract 260. Cytokine Response in the Cerebrospinal Fluid during AIDS-Associated Cryptococcus neoformans Infection: Markers of Meningeal Involvement and Potential Prognostic Indicators Abstract 261. Comparison of Antigen Clearance during Treatment of Disseminated Histoplasmosis with Itraconazole vs. Fluconazole in Patients with AIDS Abstract 262. Antimicrosporidial Effects of the Sesquiterpenes, Fumagillin, TNP-470, and Eight Ovalicin Deriviatives, In Vitro and In Vivo Abstract 263. Sequential Expression of IL-15, Interferon Gamma, and IL-4 in Cryptosporidiosis Patients during Immune Reconstitution with HAART Abstract 264. Relapsing Visceral Leishmaniasis Despite Effective Protease Inhibitor Therapy in AIDS Patients Abstract 265. Drug resistant S. typhimurium in HIV-Infected persons Abstract 266. A 2-Year, Multicenter Study of Cytomegalovirus Retinitis in AIDS Patients Receiving Protease Inhibitor Therapy Abstract 267. Long-Term Effects of HAART on Morbidity and Mortality in HIV-1-Infected Patients at Risk for CMV Disease Abstract 268. Cytomegalovirus (CMV) Immunity in HIV-Infected Patients on Highly Active Antiretroviral Therapy (HAART) Abstract 269. Progressive reduction of CMV-specific CD4+ T cells in HIV-1-Infected individuals receiving HAART Abstract 270. Immune Recovery Uveitis in Patients with AIDS and Cytomegalovirus Retinitis after Highly Active Antiretroviral Therapy Abstract 271. Reappearance of Human Cytomegalovirus DNA in Blood of HIV-Positive Patients ffter 2.5 Years of HAART Abstract 272. Recurrent Cytomegalovirus (CMV) Retinitis in a Patient on Highly Active Antiretroviral Therapy (HAART) Despite Apparent Immune Reconstitution Abstract 273. Multicenter Evaluation of CMV Reactivation in HIV-infected Women at Potential Risk for CMV Disease Abstract 274. CMV Viremia and the Risk of CMV End-Organ Disease (EOD) or Death in Patients with AIDS Abstract 275. Cytomegalovirus (CMV) Infection and HIV RNA Levels in Individuals with Hemophilia Abstract 276. High Prevalence of Anal Squamous Intraepithelial Lesions Related to HPV Infection in HIV-Infected Intravenous Drug Users Abstract 277. The Effect of CCR5D32 Heterozygosity on Hepatitis C Viral Load in HIV-1-Infected Individuals Abstract 278. Predictors of Detectable Hepatitis C Virus-RNA (HCV-RNA) Levels in HIV+/HCV+ Patients Abstract 279. Histological Damage of Hepatitis C Virus in HIV-Infected Patients Abstract 280. The Relationship between Hepatitis C Virus and HIV Infection in Hemophiliacs Abstract 281. Impact of HIV on Progression to End-Stage Liver Disease in HCV Coinfected Hemophiliacs Abstract 282. HIV-Protease Inhibitor Therapy Decreases the Liver Fibrosis Progression Rate in HIV-HCV Coinfected Patients Abstract 283. Interferon (IFN) and Ribavirin (RBV) Therapy for Hepatitis C (HCV) in HIV Coinfected Patients. 12-Month Follow-up Abstract 284. Interferon + Ribavirin in HIV+ Patients with Chronic Hepatitis C Abstract 285. HBV DNA Breakthrough during Lamivudine Therapy in HIV-HBV-Coinfected Patients under HAART Therapy Abstract 286. Failure of Sequential Nucleoside Analog Therapy for HBV in HIV-1/HBV Coinfected Individuals Abstract 287. Perivascular Brain Macrophages Are a Major Target of SIV Infection: Implications for the Neuropathogenesis of AIDS Abstract 288. Glial Differentiation, Activation, and/or Viral Infection Influence the Secretion of Matrix Metalloproteinases: Implications for HIV-1-Associated Dementia Abstract 289. a-Chemokines and their Receptors in Neuronal Signaling: Relevance for HIV-1-Associated Dementia Abstract 290. CD40L Activation of Mononuclear Phagocytes: Regulation of HIV-1 Replication , b-Chemokine Production, and b-Chemokine Receptor Expression Abstract 291. IL-8 Inhibits Neuronal Long-Term Potentiation: A Potential Mechanism for Cognitive Decline in HIV-1-Associated Dementia Abstract 292. Impairments of Blood-Brain Barrier Function in HIV-1-Associated Dementia Abstract 293. Evaluation of Highly Active Anti-Retroviral Therapeutic Regimens for Treatment of Spreading Viral Infection in Brains of SCID Mice with HIV-1 Encephalitis Abstract 294. MRI and MRS in HIV Infection Abstract 295. Investigation of the Proposed Protective Effect of HHV-8 against HIV-1-Related Dementia Abstract 296. Monocyte Immunity as a Predictor for HIV-1-Associated Dementia Abstract 297. Gender and Neurological Functioning in HIV Infection Abstract 298. Feasibility Study of the Disease Management Assistance System: A Potential Adherence Enhancing Device Abstract 299. Clinical and Virological Correlates of Longer Survival in AIDS-Associated Progressive Multifocal Leukoencephalopathy Abstract 300. Molecular Epidemiology of JCV in France: Viral Genotypes Present in Urine and CSF or Brain Biopsy in HIV-Infected Patients Abstract 301. Association of Human Herpesvirus 6 with the Demylinative Lesions of Progressive Multifocal Leukoencephalopathy Abstract 302. Incidence of Neuropathy in HIV-Infected Patients Taking Monotherapy vs. Combination Therapy with Didanosine, Stavudine, and Hydroxyurea Abstract 303. Cerebrospinal Fluid HIV-1 RNA in Patients on Suppressive Antiretroviral Therapy Abstract 304. Transient Discordant Virologic Responses in CSF and Plasma and the Trafficking of Multidrug-Resistant HIV Abstract 305. Frequent Dissociation of CSF and Plasma HIV RNA Responses during Antiretroviral Therapy (ART) Abstract 306. Changes in Cerebrospinal Fluid (CSF) after Interruption of Antiretroviral Therapy (ART): Accelerated Rise in CSF HIV-1 RNA and Accompanying CSF Pleocytosis Abstract 307. Compartmentalization and HIV-1 Migration into the Peripheral Blood and the Cerebrospinal Fluid Abstract 308. Which Single Cerebrospinal Fluid (CSF) Sample Timepoint Best Predicts Indinavir CSF AUC 0-8hr? Abstract 309. Drug Levels and HIV-1 RNA in Serum and CSF during Treatment with a Five-Drug Regimen: AZT, 3TC, Abacavir, Nevirapine (NVP), and Indinavir (IDV) Abstract 310. A Population Model-Based Approach for Determining Lamivudine (3TC) Cerebrospinal Fluid (CSF) Penetration in HIV-Infected Adults Abstract 311. Plasma Population Pharmacokinetics (PK) and CSF Penetration of Indinavir (IDV) in Combination with ZDV and 3TC in HIV-Infected Patients Abstract 312. Enhanced Penetration of Indinavir (IDV) in Cerebrospinal Fluid and Semen after Addition of Low-Dose Ritonavir (RTV) Abstract 313. Quantification of Nelfinavir (NFV) and Its Active Metabolite (M8) in CSF and Plasma, and Correlation with CSF HIV-1 RNA Response Abstract 314. Antiviral Activity and Pharmacokinetics of Amprenavir with or without Zidovudine/3TC in the Cerebral Spinal Fluid of HIV-Infected Adults Abstract 315. Penetration of Emivirine (Coactinon, EMV) in CSF from HIV-Infected Patients after Oral Administration Abstract 316. The Concentrations of D4T, 3TC, Nelfinavir (NFV), and Saquinavir (SQV) in Plasma, Cerebrospinal Fluid (CSF), and Semen Abstract 317. Analysis of Amprenavir (APV)/3TC/ZDV in Blood and Seminal Plasma: Penetration of APV into the Male Genital Tract Abstract 318. Antiretroviral Drug Concentrations in Semen of HIV-Infected Men: Differential Penetration of Indinavir (IDV), Ritonavir (RTV), and Saquinavir (SQV) Abstract 319. Immune Reconstitution and Viral Load Response In Antiretroviral Naive Vertically HIV-Infected Children Enrolled In The PENTA 5 Trial Abstract 320. Decrease in Expanded CD8 Subsets after Highly Active Antiretroviral Therapy in HIV-Infected Children Abstract 321. Perturbation of CD8 and CD4 TCR Vb Repertoire in HIV-Infected Infants Abstract 322. Reconstitution of the T Cell Pool in Treated, HIV-Infected Children Abstract 323. Thymic Emigrant Cells in Peripheral Blood of HIV-Infected Children Correlate with Response to Antiretroviral Therapy Abstract 324. Response to Childhood Immunizations in HIV-Infected Children Treated with Potent Combination Antiretroviral Therapy Abstract 325. Circulating Interleukin-7 Levels Are Correlated with T-Lymphopenia and Viral Load in HIV-1-Infected Individuals: Implications for Disease Progression Abstract 326. Increasing Thymic Output with Exogenous IL-7 Abstract 327. Poor CD4+ T Cell Responses after Suppression of HIV Replication May Reflect Thymic Failure Abstract 328. Evidence for Enhanced Thymic Output, Measured by T Cell Receptor Excision Circles (TRECS), after HAART Abstract 329. Primary HIV Infection Results in a Potent Thymic Rebound Abstract 330. Maximum Suppression of HIV in Early HIV Disease Leads to the Restoration of HIV-p24 Response and an Early Rise in Naive T Cells Abstract 331. Evidence for Comparable Immune Restoration between a PI-Based Triple Antiretroviral Therapy (IDV/COM): CNA3005 Abstract 332. Responses of HIV-1 p24 and HIV-1 RNA in Tonsils of Asymptomatic HIV-1 Infected-Patients under Combination Antiretroviral Therapy Abstract 333. Discordant Immunological and Virological Responses to HAART Abstract 334. Clinical Outcome, CD4+ Cell Count, and HIV-1 Reverse Transcriptase (RT) and Protease (PT) Sequences in Patients Remaining Viremic during HAART Abstract 335. Continued Suppression of Plasma Viral Load Is Needed to Achieve an Optimal CD4 Response among Patients Receiving Triple Drug Antiretroviral Therapy Abstract 336. Immunologic and Virologic Responses after Long-Term HAART in HIV-1-Infected Therapy: Naive Adults at Early Stage of Chronic Infection Abstract 337. Differences in T-Cell Subset Reconstitution after 12 Months of HAART in Early vs. Advanced HIV-1 Disease Abstract 338. Implication of Interferon-a (IFN-a) Generation in Immune Reconstitution during Antiretroviral Therapy for Human Immunodeficiency Virus Infection Abstract 339. Thyroid Autoimmunity (Graves' Disease) after Immune Restoration in HIV-Infected Patients Receiving HAART Abstract 340. Cell Kinetic Patterns and Their Relationships with Virologic Responses in HIV-1-Infected Patients Treated with HAART Abstract 341. Effects of Combined Treatment with Interleukin-2 (IL-2) and an Inactivated gp120-Depleted HIV-1 Immunogen (REMUNE) on Immune Reconstitution in HAART-Treated, HIV-1-Infected Individuals Abstract 342. Effects of Highly Active Antiretroviral Therapy (HAART) on Cell-Mediated Immunity in Children with Stable HIV Infection Abstract 343. CD4 T Cell Recovery Is Slower in Patients Experiencing Viral Load Rebounds during HAART Abstract 344. Long-Term Kinetics of T Cell Production in HIV-Infected Subjects Treated with Highly Active Antiretroviral Therapy (HAART) Abstract 345. Comparison of Immune Reconstitution in Subjects Treated with HAART during Primary and Chronic HIV-1 Infection Abstract 346. Safety and Immunogenicity Study on vCP1452/gp160 Vaccine in Patients Treated with HAART for Over Two Years Abstract 347. Enhancement of HIV-1 Antigen-Specific CD4+ T Cell Frequencies in HIV-1 Seropositive Subjects after Treatment with an HIV-1 Immunogen Abstract 348. Vaccine-Specific Immune Responses in HIV-Infected Volunteers Post-Active Immunotherapy with Whole, Inactivated HIV Abstract 349. Plasma Viral Loads Approximate Pre-HAART Levels after Discontinuation of HAART Abstract 350. Immunophenotyping during Virologic Remission and Relapse on Antiretroviral Therapy Abstract 351. No Detectable HIV RNA in Thirteen Individuals Months after Stopping Antiretroviral Therapy Abstract 352. Control of Viremia after Treatment Interruption Abstract 353. Boosting of HIV-1-Specific Cellular Immune Responses in Chronically Infected Persons after Treatment Interruption Abstract 354. Structured Treatment Interruption in Chronically HIV-1 Infected Patients after Long-Term Viral Suppression Abstract 355. Cessation of HAART Plus Daily Low-Dose Interleukin 2 to Promote Immunity to HIV Abstract 356. Intermittent Interruptions of Antiretroviral Therapy in Chronically HIV-Infected Patients Do Not Induce Immune Control of HIV Abstract 357. Increase in Breadth and Frequency of CTL Responses after Structured Therapy Interruptions in Individuals Treated with HAART during Acute HIV-1 Infection Abstract 358. Rapid Activation of Lymph Nodes upon Interrupting HAART in HIV-Infected Patients after Prolonged Viral Suppression Abstract 359. Significant Delay in Plasma vRNA Rebound during a Scheduled Treatment Interruption in HIV-1 Chronically Infected Patients Previously on Effective Therapy Abstract 360. Dynamics of HIV-1 Viral Load Rebound among Patients with Previous Suppression of Viral Replication Abstract 361. Inhibition of Interleukin-12 Production in Human Monocyte-Derived Macrophages by Tumor Necrosis Factor Abstract 362. HIV Replication in Macrophages Isolated from HIV-Infected Patients Receiving Protease Inhibitors Abstract 363. HIV Is Expressed Preferentially by CD4 T-Cells That Coexpress CD45RO and CD45RA Abstract 364. Reversal of HIV-Related Neutrophil Dysfunction with Interleukin-15 Abstract 365. Normalization of Natural Killer (NK) Cell Activity with Effective Antiretroviral Therapy (ART) May Be Caused by Restoration of NK Cell Receptor Expression Abstract 366. In Vivo Effects of G-CSF on Lymphocyte Subsets, Monocytes, Cytokine Release, and Proviral DNA: An Exploratory Study Abstract 367. Effects of G-CSF on Neutrophil Function and Apoptosis in HIV Patients: A Randomized Dose-Ranging Trial Abstract 368. NK Cells, but Not CD8+ Cells, in HIV-Infected Lymph Nodes Maintain Both Granzyme B and Perforin Expression Abstract 369. Differentiation of Trev-Transduced CD34+ Progenitors into Cells Coexpressing CD4 and CCR5 Abstract 370. Immunologic Responses in Patients with Virologic Response to Antiretroviral Therapy Is Associated with a Decreased Rate of Ex Vivo Apoptosis Abstract 371. Lymphocyte Migration to the Gut in HIV-1 Infection and HAART Abstract 372. S Phase Lymphocytes of HIV-1-Infected Patients Preferentially Undergo Apoptosis Abstract 373. A Controlled Trial of Cyclosporine (CsA) in HIV Infection Abstract 374. Increased Levels of Activated Functionally Distinct Subsets of CD4 in HIV Infection Add to the Prognostic Value of Low CD4+ T-Cell Counts in a Cohort of Seropositive Intravenous Drug Users: Results of 4 Years of Follow-Up Abstract 375. Antigenic Stimulation Accounts for Most of the Hyperactivation of CD4+ and CD8+ T-Cells in HIV Infection Abstract 376. Primary Immune in Chronic HIV-Infected Patients on HAART Are Predicted by the Numbers of PMA/Ionomycin-Induced CD4+ IL-2+ T cells Abstract 377. Initial Potent T Cell Activation Driven by Mycobacterium bovis BCG Is Associated with Short-Term Containment of Virus Infection in Early SIVmac-Infected Macaques Abstract 378. In Vitro, Recombinant Interleukin-2 and HIV-Specific Antigens Activate HIV Latently Infected Lymphocytes from Patients on Prolonged HAART Abstract 379. Cytokine Activation in HIV+ Individuals Receiving IL-2 and Antiretrovirals. Results from a Randomized 4-Arms Trial Abstract 380. Twenty-Month Follow-up of The Argentina Vanguard Study: A Randomized, Controlled, Phase II Trial of Intermittent Subcutaneous Interleukin-2 (scIL2) Plus Antiretroviral Therapy (ARV) vs. ARV Alone Abstract 381. Low-Dose Subcutaneous (SC) IL-2 in Combination with HAART Therapy Induces Significant Increases in NK Cells and Naive T-cells in Patients with <300 CD4+ T-cells/mm3: Results of a Randomized Controlled Trial MA-9801 Abstract 382. Apoptosis Rates of T-Lymphocytes in HIV Patients Increase during Intermittent Administration of Interleukin-2 Abstract 383. Immonological and Virological Efficacy of Long-Term IL-2 Therapy in HIV-Infected Patients Abstract 384. Constitutive Levels of Chemokine mRNA in CD4 Cells from HIV-Infected Children Can Indicate Their Disease Status and Response to Therapy Abstract 385. Downregulation of CCR5 mRNA in Lung and Blood Cells of Asymptomatic HIV-Seropositive Persons Abstract 386. Immune Activation in African HIV Infection Favors CCR5-Dependent Strains of HIV Abstract 387. Assessment of b Chemokines in HIV-1 Infected Individuals: Impact of Highly Active Antiretroviral Therapy (HAART) Abstract 388. C/EBPb (NF-IL6) Stimulates CCR5 Expression: Increased C/EBPb and CCR5 in T-Lymphocytes from HIV-1 Patients Abstract 389. Single-Cell Analysis of Cytokine (IL-2, IL-4, IFN-g) and Beta Chemokine (MIP-1a, MIP-1b, RANTES) Production by CD4+ (CD8-) and CD8+ T-Lymphocytes from HIV-1-Infected Long-Term Nonprogressors and Progressors Abstract 390. Macaque Resistance to Mucosal SIV Infection Is not Associated with Changes in CCR5 Coding Sequence Abstract 391. Alteration of Homeostasis of Naive and Memory IL-2-and TNF&-T Cell Producers after HAART: Consequences on Lipodystrophy Abstract 392. TH-1 Cytokine Responses to HCMV Can Be Detected in PBMC and Whole Blood Abstract 393. The Level of RANTES Expression and HIV-1 Replication in the Lymphoid Tissues of HIV-1-Infected Acute and Chronic Patients Abstract 394. HIV-1 Gag Binding of Cellular Actin and Virus Infectivity Abstract 395. Formation of HIV-1 Assembly Intermediate Complex and the Role of Capside-P2 Boundary Region Abstract 396. The Cytoplasmic Interaction of HIV-1 Precursor Proteins Pr55gag and Pr160gag-pol Requires RNA Abstract 397. Characterization of HIV-1 Virus Assembly Complexes Abstract 398. Mapping and Characterization of the N-Terminal I Domain of HIV-1 Pr55Gag Abstract 399. Sequences within Pr160gag-pol Affecting the Selective Packaging of tRNALys3 into HIV-1 Abstract 400. Indentification of the gp41 Cytoplasmic Tail Domains of HIV-1 That Interact with Pr55gag Particles Abstract 401. The N-Terminal Matrix Domain of HIV-1 Gag Is Sufficient but Not Necessary for Vpu-Mediated Enhanced Viral Release Abstract 402. Determinants of the Specificity of Tat:TAR and NCp7:Leader Interaction: Cross-Transactivation between HIV-1 and HIV-2 Abstract 403. Point Mutations in the U5 Region and Gag Proteins Can Rescue Deletions in the RNA Leader Sequence in Regard to Replication of HIV-1 Abstract 404. A Novel Biosensor Assay for Studying HIV Envelope-Chemokine Receptor Interactions Abstract 405. The Sensitivity of Primate Lentiviruses to CCR5- and CXCR4-Specific Inhibitors Abstract 406. Non-CCR5 Pathway(s) in Human Macrophages Support Simian Immunodeficiency Virus (SIV) Fusion Abstract 407. Distinct R5 and X4 Env Clones within the Quasispecies of the R5X4 Dual-Tropic HIV-1 89.6 Primary Isolate: Molecular Basis for M- to T-Tropic Phenotype Transition In Vivo Abstract 408. Enhancement of Virus Infectivity: Characterization of a Signaling Pathway Utilized by the CC-Chemokine RANTES to Induce Signals through Interaction with Glycosoaminoglycan Receptors Abstract 409. RANTES-Induced Enhancement of Virus Infectivity: Cell Compartments Involved in Mediating the RANTES Signal and Their Link to the Virus Life Cycle Abstract 410. HIV-1 gp120 and Chemokines Elicit Distinct Patterns of Ion Channel Activation via CCR5 and CXCR4 in Macrophages Abstract 411. Entry of R5X4 and X4 HIV-1 Strains Is Mediated by Negatively Charged and Tyrosine Residues in the Amino-Terminal Domain and the Second Extracellular Loop of CXCR4 Abstract 412. Role of Coreceptor Aggregation and MAP Kinase Activation in HIV Infection Abstract 413. In Vivo Selected HIV-1 Isolate Shows Altered Tropism without Shift in Coreceptor Usage Abstract 414. Down-Regulation of Surface CXCR4 on CD4-Positive or -Negative Cell Lines: Role of the CD4-Independent HIV-1 Isolate m7NDK gp160 Abstract 415. Tissue Tropism of HIV-1 and Coreceptor Use Abstract 416. Characterization of the CCR3 Transcription Unit Abstract 417. Characterization of STRL33 Expression and Coreceptor Activity Abstract 418. Functional Isolation of a Novel HIV Coreceptor (CCRX): A Potential Receptor for the Macrophage-Derived Chemokine (MDC) Abstract 419. Functional Responses of Human Primary Cells to HIV-1 Envelope Glycoprotein, gp120 Abstract 420. Native, Oligomeric Envelope Is Resistant to Digestion by Glycosidases Abstract 421. Analysis of Mutations in the Intracytoplasmic Domain of the HIV-1 Env Gene That Block Viral Replication Abstract 422. Pertussis Toxin-Insensitive Signaling Is Required for the Entry of HIV-1 into Primary T Lymphocytes Abstract 423. Inefficient Entry of a Cytopathic Primary HIV-1 Isolate into Cell Lines Abstract 424. Analysis of the Interaction between gp120 V3 Region and Coreceptors by Using Chimeric Env-Pseudotyped Viruses (I): Requirement of Binding of the V3 Region, Regardless of the Amino Acid Sequence, to Corresponding Chemokine Receptors Abstract 425. Soluble CD4 Activates HIV-1 Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120 Abstract 426. Differential Acquisition of Host Cell Surface Proteins on HIV-1 Clinical Strains Grown on PBMC and Monocyte-Derived Macrophages Abstract 427. Neutralization Sensitivity of HIV-1 Particles Is Significantly Decreased by Interactions between Virion-Bound Host ICAM-1 and the High-Affinity Form of LFA-1 on Target Cells L3 Management of the HIV Infected Pregnant Woman L4 HIV Entry and Its Inhibition S12 A Randomized Trial of Single Dose Nevirapine to Mother and Infant Versus Azidothymidine in Kampala, Uganda for Prevention of Mother-To-Infant Transmission of HIV-1 (HIVNET 012) S13 Breastmilk Transmission of HIV-1 S14 Mitochondrial Toxicity of Perinatally Administered Zidovudine S16 Development and Clinical Evaluation of T-20: The First Member of a Novel Class of Anti-Retroviral Agents that Inhibit Membrane Fusion S17 A Small Molecule Antagonist of CCR5 that Effectively Inhibits HIV-1 Potential as a Novel Antiretroviral Agent S18 Bicyclams as CXCR4 Antagonists S19 New Drug Targets: Entry Inhibitors: Clinical Summary S20 Abnormalities of Body Composition and Lipids Associated with HAART: Pathogenesis, Clinical Manifestations, and Case Definitions S22 Evaluation of the Metabolic Complications of HAART: An Industry and Academic Initiative S23 Fat Redistribution and Metabolism (FRAM) Study: A U.S. National Investigative Collaboration